149 related articles for article (PubMed ID: 24729186)
1. Circulating levels of soluble Fas ligand reflect disease progression in multiple myeloma.
Alexandrakis MG; Pappa CA; Kolovou A; Kyriakaki S; Vyzoukaki R; Devetzoglou M; Tsirakis G
Med Oncol; 2014 May; 31(5):953. PubMed ID: 24729186
[TBL] [Abstract][Full Text] [Related]
2. Elevated levels of soluble Fas (APO-1, CD95), soluble Fas ligand, and matrix metalloproteinase-3 in sera from patients with active untreated adult onset Still's disease.
Chen DY; Lan JL; Lin FJ; Hsieh TY
Clin Rheumatol; 2007 Mar; 26(3):393-400. PubMed ID: 16972019
[TBL] [Abstract][Full Text] [Related]
3. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure.
Nishigaki K; Minatoguchi S; Seishima M; Asano K; Noda T; Yasuda N; Sano H; Kumada H; Takemura M; Noma A; Tanaka T; Watanabe S; Fujiwara H
J Am Coll Cardiol; 1997 May; 29(6):1214-20. PubMed ID: 9137215
[TBL] [Abstract][Full Text] [Related]
4. Increased serum soluble Fas after major trauma is associated with delayed neutrophil apoptosis and development of sepsis.
Paunel-Görgülü A; Flohé S; Scholz M; Windolf J; Lögters T
Crit Care; 2011; 15(1):R20. PubMed ID: 21232130
[TBL] [Abstract][Full Text] [Related]
5. Serum Levels of Soluble FLT3 Ligand in Patients with Active Multiple Myeloma Constitute Marker of Bone Marrow Plasma Cell Proliferative Activity.
Kokonozaki M; Kanellou P; Pappa CA; Vyzoukaki R; Sarantoulaki S; Stavroulaki E; Kyriakaki S; Alegakis A; Boula A; Alexandrakis MG
Crit Rev Oncog; 2017; 22(3-4):255-262. PubMed ID: 29604902
[TBL] [Abstract][Full Text] [Related]
6. [Role of soluble Fas ligand in myocardial remodeling, severity and outcomes of chronic heart failure].
Teplyakov AT; Berezikova EN; Shilov SN; Grakova EV; Torim YY; Efremov AV; Popova AA; Pustovetova MG; Sabirova AY; Kopyeva KV
Ter Arkh; 2016; 88(9):10-16. PubMed ID: 27735908
[TBL] [Abstract][Full Text] [Related]
7. An increase of soluble Fas, an inhibitor of apoptosis, associated with progression of COPD.
Yasuda N; Gotoh K; Minatoguchi S; Asano K; Nishigaki K; Nomura M; Ohno A; Watanabe M; Sano H; Kumada H; Sawa T; Fujiwara H
Respir Med; 1998 Aug; 92(8):993-9. PubMed ID: 9893764
[TBL] [Abstract][Full Text] [Related]
8. Proinflammatory cytokine activation is linked to apoptotic mediator, soluble Fas level in patients with chronic heart failure.
Kinugawa T; Kato M; Yamamoto K; Hisatome I; Nohara R
Int Heart J; 2012; 53(3):182-6. PubMed ID: 22790687
[TBL] [Abstract][Full Text] [Related]
9. Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus.
Vincent FB; Kandane-Rathnayake R; Koelmeyer R; Harris J; Hoi AY; Mackay F; Morand EF
Lupus Sci Med; 2020 Jun; 7(1):. PubMed ID: 32546562
[TBL] [Abstract][Full Text] [Related]
10. Soluble Fas might serve as a diagnostic tool for gastric adenocarcinoma.
Boroumand-Noughabi S; Sima HR; Ghaffarzadehgan K; Jafarzadeh M; Raziee HR; Hosseinnezhad H; Moaven O; Rajabi-Mashhadi MT; Azarian AA; Mashhadinejad M; Tavakkol-Afshari J
BMC Cancer; 2010 Jun; 10():275. PubMed ID: 20534173
[TBL] [Abstract][Full Text] [Related]
11. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS
Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
[TBL] [Abstract][Full Text] [Related]
12. [Change in serum levels of soluble Fas and soluble FasL in patients with multiple organ dysfunction syndrome].
Fu Y; Xiao QM; Wang T; Chen XH; Ai YH
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2006 Nov; 18(11):691-4. PubMed ID: 17092425
[TBL] [Abstract][Full Text] [Related]
13. Serum soluble CD40L concentration depending on the stage of multiple myeloma and its correlation with selected angiogenic cytokines.
Kamińska J; Koper OM; Dymicka-Piekarska V; Motybel-Iwańczuk E; Ołdziej A; Kemona H
Pol Arch Med Wewn; 2016 May; 126(5):321-9. PubMed ID: 27243341
[TBL] [Abstract][Full Text] [Related]
14. [Clinical significances of serum soluble fas and soluble fas ligand in chronic hepatitis B].
Jun EJ; Han JY; Sun HS
Korean J Hepatol; 2006 Dec; 12(4):507-14. PubMed ID: 17237628
[TBL] [Abstract][Full Text] [Related]
15. Soluble Fas and Fas ligand and prognosis in children with acute lymphoblastic leukemia.
Fathi M; Amirghofran Z; Shahriari M
Med Oncol; 2012 Sep; 29(3):2046-52. PubMed ID: 21528407
[TBL] [Abstract][Full Text] [Related]
16. Soluble fas levels correlate with multiple organ dysfunction severity, survival and nitrate levels, but not with cellular apoptotic markers in critically ill patients.
Papathanassoglou ED; Moynihan JA; Vermillion DL; McDermott MP; Ackerman MH
Shock; 2000 Aug; 14(2):107-12. PubMed ID: 10947151
[TBL] [Abstract][Full Text] [Related]
17. Circulating levels of soluble Fas ligand and soluble Fas in patients with chronic obstructive pulmonary disease.
Takabatake N; Nakamura H; Inoue S; Terashita K; Yuki H; Kato S; Yasumura S; Tomoike H
Respir Med; 2000 Dec; 94(12):1215-20. PubMed ID: 11192958
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of a combination of soluble Fas and soluble Fas ligand in the serum of patients with Ta bladder cancer.
Mizutani Y; Yoshida O; Ukimura O; Kawauchi A; Bonavida B; Miki T
Cancer Biother Radiopharm; 2002 Oct; 17(5):563-7. PubMed ID: 12470426
[TBL] [Abstract][Full Text] [Related]
19. Expression of Fas ligand and sFas ligand in human gastric adenocarcinomas.
Lim SC
Oncol Rep; 2002; 9(1):103-7. PubMed ID: 11748465
[TBL] [Abstract][Full Text] [Related]
20. [Serum level and urinary excretion of soluble Fas (sFas) in patients with primary glomerulopathies].
Kacprzyk F
Pol Arch Med Wewn; 2002 Sep; 108(3):843-7. PubMed ID: 12600180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]